Rivaroxaban

Summary

Rivaroxaban (CHEMBL198362) is an approved small-molecule anticoagulant (ATC B01AF01) targeting F10; indicated across 38 conditions including atrial fibrillation and venous thromboembolism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B01AF01
• Targets: 1 (F10)
• Indications: 38 conditions
• Clinical trials: 293
• Chemistry: 435.9 Da · C19H18ClN3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL198362
Name	Rivaroxaban
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9875401
ChEBI	CHEBI:68579
ATC	B01AF01
Molecular formula	C19H18ClN3O5S
Molecular weight	435.9
InChIKey	KGFYHTZWPPHNLQ-AWEZNQCLSA-N

SMILES: C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl

IUPAC name: 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide

ChEBI definition: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.

Pharmacological roles (ChEBI): anticoagulant, EC 3.4.21.6 (coagulation factor Xa) inhibitor.

Also known as: JNJ-39039039, JNJ39039039, Rivaroxaban, Rivaroxaban accord, Xarelto, rivaroxaban, RIVAROXABAN, RIVAROXABAN (XARELTO), RivaroxabanÊ, Rivaroxaban (Xarelto), RivaroxabanÂ

Patent coverage: 3,275 distinct patent families (11,497 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
F10	coagulation factor X	Inhibition	9.4	0%	P00742

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Prothrombin, Coagulation factor X, Suppressor of tumorigenicity 14 protein, Coagulation factor X, Bile salt export pump.

Bioactivity

ChEMBL activities: 24 potent at pChembl ≥ 5 of 25 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
F10	9.4	Ki	0.4	nM	CHEMBL_ACT_13843677
F10	9.4	Ki	0.4	nM	CHEMBL_ACT_18652561
F10	9.4	Ki	0.4	nM	CHEMBL_ACT_2517460
F10	9.4	Ki	0.4	nM	CHEMBL_ACT_3515228
F10	9.18	Ki	0.66	nM	CHEMBL_ACT_13338526
F10	9.15	Ki	0.7	nM	CHEMBL_ACT_13970477
F10	9.15	IC50	0.7	nM	CHEMBL_ACT_1607460
F10	9.15	IC50	0.7	nM	CHEMBL_ACT_22431922
F10	9.15	IC50	0.7	nM	CHEMBL_ACT_25028352
F10	9.15	IC50	0.7	nM	CHEMBL_ACT_3515012
F10	8.85	IC50	1.4	nM	CHEMBL_ACT_17601310
F10	8.8	IC50	1.6	nM	CHEMBL_ACT_12056543
F10	8.68	IC50	2.1	nM	CHEMBL_ACT_26024757
F10	8.66	IC50	2.2	nM	CHEMBL_ACT_15223629
F10	8.47	Ki	3.4	nM	CHEMBL_ACT_18890999
F10	8.34	IC50	4.59	nM	CHEMBL_ACT_12072076
F10	8.22	IC50	6	nM	CHEMBL_ACT_25587870
F10	8.07	IC50	8.52	nM	CHEMBL_ACT_15076246
F10	7.84	IC50	14.4	nM	CHEMBL_ACT_15704078
F10	6.4	IC50	400	nM	CHEMBL_ACT_15223492
O19045	6.29	IC50	510	nM	CHEMBL_ACT_15223593
F2	6.11	AC50	770	nM	CHEMBL_ACT_25197061
O19045	6.07	IC50	860	nM	CHEMBL_ACT_15223623
ST14	5.47	Ki	3350	nM	CHEMBL_ACT_15176512

Target pathways

Aggregated over 1 target gene(s): F10.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
R-HSA-140834	1	F10
R-HSA-140837	1	F10
R-HSA-140875	1	F10
Gamma-carboxylation of protein precursors	1	F10
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus	1	F10
Removal of aminoterminal propeptides from gamma-carboxylated proteins	1	F10
Defective factor IX causes thrombophilia	1	F10
Defective cofactor function of FVIIIa variant	1	F10
Defective F9 variant does not activate FX	1	F10
Initiation of coagulation cascade	1	F10
Regulation of clotting cascade	1	F10
Amplification and propagation of coagulation cascade	1	F10

Dominant GO biological processes

GO term	Targets
proteolysis	1
blood coagulation	1
positive regulation of cell migration	1
positive regulation of TOR signaling	1
hemostasis	1

Indications & clinical

Indications

8 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
atrial fibrillation	4	MONDO:0004981	EFO:0000275
venous thromboembolism	4	MONDO:0005399	EFO:0004286
acute coronary syndrome	4	MONDO:0005542	EFO:0005672
pulmonary embolism	4	MONDO:0005279	EFO:0003827
thrombotic disease	4	MONDO:0000831	HP:0004419
stroke disorder	4	MONDO:0005098	EFO:0000712
peripheral arterial disease	4	MONDO:0005386	EFO:0004265
coronary artery disorder	4	MONDO:0005010	EFO:0001645

19 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
neoplasm	3	MONDO:0005070	EFO:0000616
rheumatic heart disease	3	MONDO:0006955	EFO:1001161
myocardial infarction	3	MONDO:0005068	EFO:0000612
severe acute respiratory syndrome	3	MONDO:0005091	EFO:0000694
kidney failure	3	MONDO:0001106	HP:0000083
thrombocytopenia	3	MONDO:0002049	HP:0001873
aortic valve stenosis	3	MONDO:0042981	EFO:0000266
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
hip fracture	3	MONDO:0005327	EFO:0003964
intermediate coronary syndrome	3	MONDO:0006805	EFO:1000985
ischemic disease	2	MONDO:0005053	EFO:0000556
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
heart disorder	2	MONDO:0005267	EFO:0003777
aortic valve disorder	2	MONDO:0003803	EFO:0009531
sickle cell disease	2	MONDO:0011382	MONDO:0011382
chronic kidney disease	1	MONDO:0005300	EFO:0003884
morbid obesity	1	MONDO:0005139	EFO:0001074
blood coagulation disease	1	MONDO:0001531	EFO:0009314

11 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 293.

Phase distribution

Phase	Trials
PHASE4	77
PHASE3	76
Not specified	76
PHASE2	28
PHASE1	23
PHASE2/PHASE3	8
PHASE1/PHASE2	3
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03129490	PHASE4	ACTIVE_NOT_RECRUITING	The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
NCT03129555	PHASE4	ACTIVE_NOT_RECRUITING	The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
NCT03568890	PHASE4	ACTIVE_NOT_RECRUITING	Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
NCT04258488	PHASE4	RECRUITING	Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement
NCT04263038	PHASE4	RECRUITING	Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04642430	PHASE4	RECRUITING	COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
NCT05180773	PHASE4	RECRUITING	Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05487950	PHASE4	NOT_YET_RECRUITING	Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
NCT05638867	PHASE4	RECRUITING	NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05735639	PHASE4	RECRUITING	THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
NCT05794399	PHASE4	RECRUITING	Anticoagulation in Post MI LV Thrombus Trial in Nepal
NCT06108414	PHASE4	RECRUITING	Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
NCT06187311	PHASE4	RECRUITING	Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
NCT06396858	PHASE4	NOT_YET_RECRUITING	Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
NCT06476301	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves
NCT06650501	PHASE4	RECRUITING	Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
NCT06812455	PHASE4	RECRUITING	Effect of RIVAroxaban in Radial Artery Occlusion Treatment After Cardiac Catheterization
NCT06953726	PHASE4	NOT_YET_RECRUITING	Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
NCT06978439	PHASE4	RECRUITING	Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
NCT07195812	PHASE4	NOT_YET_RECRUITING	Rivaroxaban for Slow Coronary Flow After PCI in STEMI
NCT07243080	PHASE4	RECRUITING	Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
NCT07404436	PHASE4	RECRUITING	Rivaroxaban in Idiopathic Membranous Nephropathy
NCT07511257	PHASE4	RECRUITING	Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia
NCT01210755	PHASE4	COMPLETED	Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
NCT01478282	PHASE4	UNKNOWN	Reversal of the Antithrombotic Action of New Oral Anticoagulants
NCT01708850	PHASE4	COMPLETED	Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)
NCT01747746	PHASE4	COMPLETED	Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
NCT01812200	PHASE4	COMPLETED	Antithrombotic Triple Therapy in Humans
NCT01989845	PHASE4	COMPLETED	Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
NCT02047006	PHASE4	COMPLETED	Dose-finding of Rivaroxaban in Hemodialysis
NCT02054936	PHASE4	WITHDRAWN	Evaluation of Wound Drainage After Knee or Hip Arthroplasty
NCT02116036	PHASE4	COMPLETED	Rivaroxaban for Antiphospholipid Antibody Syndrome
NCT02161965	PHASE4	COMPLETED	Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
NCT02168829	PHASE4	COMPLETED	Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
NCT02331602	PHASE4	UNKNOWN	Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
NCT02334254	PHASE4	UNKNOWN	Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
NCT02376010	PHASE4	COMPLETED	Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
NCT02379663	PHASE4	COMPLETED	Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
NCT02453802	PHASE4	UNKNOWN	Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty
NCT02458729	PHASE4	COMPLETED	The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis
NCT02506985	PHASE4	TERMINATED	XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis
NCT02549963	PHASE4	UNKNOWN	Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban
NCT02559856	PHASE4	COMPLETED	Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
NCT02584660	PHASE4	COMPLETED	A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
NCT02610933	PHASE4	COMPLETED	Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
NCT02642419	PHASE4	UNKNOWN	Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study
NCT02666157	PHASE4	UNKNOWN	Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
NCT02723981	PHASE4	WITHDRAWN	COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
NCT02810704	PHASE4	COMPLETED	Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02935855	PHASE4	COMPLETED	ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
NCT02970773	PHASE4	WITHDRAWN	Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
NCT02974920	PHASE4	UNKNOWN	Rivaroxaban or Aspirin for Biological Aortic Prosthesis
NCT03196349	PHASE4	TERMINATED	Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism
NCT03266783	PHASE4	COMPLETED	Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
NCT03328832	PHASE4	COMPLETED	Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty
NCT03363035	PHASE4	COMPLETED	Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
NCT03413618	PHASE4	COMPLETED	Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
NCT03463317	PHASE4	COMPLETED	Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
NCT03490994	PHASE4	UNKNOWN	Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)
NCT03673605	PHASE4	WITHDRAWN	Efficacy and Safety of Rivaroxiban Compare With Vitamin K Antagonist Warfarin
NCT03749057	PHASE4	COMPLETED	Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
NCT04006288	PHASE4	COMPLETED	Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
NCT04073316	PHASE4	UNKNOWN	AntiCoagulants and COGnition
NCT04135677	PHASE4	UNKNOWN	Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
NCT04169269	PHASE4	UNKNOWN	Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
NCT04256525	PHASE4	UNKNOWN	Prophylactic Anticoagulation for Catheter-related Thrombosis
NCT04757857	PHASE4	TERMINATED	COVID-19 Antithrombotic Rivaroxaban Evaluation
NCT04794569	PHASE4	TERMINATED	Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
NCT04970576	PHASE4	COMPLETED	Rivaroxaban in Left Ventricular Thrombus
NCT04990791	PHASE4	COMPLETED	WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
NCT05116995	PHASE4	UNKNOWN	Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
NCT05303818	PHASE4	UNKNOWN	Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
NCT05671276	PHASE4	UNKNOWN	Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion
NCT05797376	PHASE4	COMPLETED	Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation
NCT06019741	PHASE4	COMPLETED	Rivaroxaban Post Coronary Bypass Surgery
NCT06103266	PHASE4	UNKNOWN	Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
NCT06314763	PHASE4	COMPLETED	Rivaroxaban Sotorasib Interaction Study
NCT05029063	PHASE3	RECRUITING	Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
NCT05035277	PHASE3	RECRUITING	AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
NCT05047172	PHASE3	ACTIVE_NOT_RECRUITING	Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05920343	PHASE2/PHASE3	RECRUITING	VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
NCT06195540	PHASE3	RECRUITING	RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
NCT06370273	PHASE3	RECRUITING	Thromboprophylaxis in Lower Limb Immobilisation
NCT06580223	PHASE3	NOT_YET_RECRUITING	Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
NCT06780462	PHASE3	RECRUITING	Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet’s Syndrome
NCT07228663	PHASE3	NOT_YET_RECRUITING	Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
NCT07318610	PHASE3	RECRUITING	Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07468448	PHASE3	NOT_YET_RECRUITING	Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
NCT00329628	PHASE3	COMPLETED	Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
NCT00332020	PHASE3	COMPLETED	Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
NCT00361894	PHASE3	COMPLETED	Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
NCT00403767	PHASE3	COMPLETED	An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
NCT00494871	PHASE3	COMPLETED	Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
NCT00571649	PHASE3	COMPLETED	Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
NCT00809965	PHASE3	COMPLETED	An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
NCT01094886	PHASE3	COMPLETED	Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
NCT01205932	PHASE3	COMPLETED	Dose-confirmatory Bridging Study in Total Hip Replacement
NCT01206972	PHASE3	COMPLETED	Dose-confirmatory Bridging Study in Total Knee Replacement
NCT01431456	PHASE3	COMPLETED	Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
NCT01499953	PHASE3	COMPLETED	Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 4 clinical and 65 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

21 molecules share ≥1 primary target. Top 21 by shared-target count:

Molecule	Source	Status	Shared targets
APIXABAN	ChEMBL + PubChem	Phase 4 (approved)	F10
EDOXABAN	ChEMBL + PubChem	Phase 4 (approved)	F10
ARGATROBAN	ChEMBL	Phase 4 (approved)	F10
BETRIXABAN	ChEMBL	Phase 4 (approved)	F10
FONDAPARINUX	ChEMBL	Phase 4 (approved)	F10
MELAGATRAN	ChEMBL	Phase 4 (approved)	F10
PENTAMIDINE	ChEMBL	Phase 4 (approved)	F10
DABIGATRAN	ChEMBL	Phase 3	F10
DAREXABAN	ChEMBL	Phase 3	F10
GABEXATE	ChEMBL	Phase 3	F10
NAFAMOSTAT	ChEMBL	Phase 3	F10
OTAMIXABAN	ChEMBL	Phase 3	F10
EFEGATRAN	ChEMBL	Phase 2	F10
ERIBAXABAN	ChEMBL	Phase 2	F10
FIDEXABAN	ChEMBL	Phase 2	F10
GW813893	ChEMBL	Phase 2	F10
LETAXABAN	ChEMBL	Phase 2	F10
LY-517717	ChEMBL	Phase 2	F10
RAZAXABAN	ChEMBL	Phase 2	F10
SEGATROXABAN	ChEMBL	Phase 2	F10
TANOGITRAN	ChEMBL	Phase 2	F10